A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

A Phase I Study to Investigate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics(PK) of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

A Phase 1, open label, multi center, dose escalation and expansion study will assess the safety, tolerability, PK, and preliminary efficacy of SCR-6920 capsule in participants with advanced malignant tumors. The purpose of the study is to identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D), and to confirm the tolerability and preliminary efficacy of SCR-6920 in participants with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma(NHL).

Study Overview

• Status: Recruiting
• Conditions: Solid Tumor; Non Hodgkin Lymphoma
• Intervention / Treatment: Drug: SCR-6920 capsule; Drug: SCR-6920 capsule

• Study Type: Interventional
• Enrollment (Anticipated): 122
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Shandong
    • Jinan, Shandong, China, 250117
      • Recruiting
      • Shandong Cancer Hospital
      • Contact: Jinming Yu; Phone Number: 0531-67626971; Email: sdyujinming@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologically or cytologically confirmed locally advanced or metastatic solid tumors or histopathologically confirmed NHL
• Relapsed/refractory solid tumor or relapsed/refractory NHL who have progressed during or after standard therapy or for which treatment is not tolerated, not suitable, not available.
• At least one evaluable or measurable lesion (as defined in the protocol).
• ECOG Performance Status 0 or 1.
• Life expectancy ≥12 weeks.
• Adequate organ function (as defined in the protocol).
• Reproductive criteria (as defined in the protocol).

Exclusion Criteria:

• Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption.
• Major surgery, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry. Radiation therapy within 2 weeks prior to study entry.
• Adverse reactions from previous anti-tumor therapy have not yet recovered to ≤ grade 1(excluding hair loss, peripheral neurotoxicity caused by chemotherapy have recovered to ≤ grade 2 ).
• Autologous hematopoietic stem cell transplantation was performed within 9 months prior to the first dose.
• History of a second malignancy within 2 years (as defined in the protocol).
• Active uncontrolled or symptomatic lung disease (as defined in the protocol).
• Intracranial hypertension or active uncontrolled or symptomatic CNS metastases.
• Known or suspected hypersensitivity to study medications.
• Known active uncontrolled or symptomatic CNS metastases.
• The investigator determined that the patient should not participate in the study.
• Known mental illness or substance abuse that may disrupt therapy.
• Clinically significant cardiac abnormalities (as defined in the protocol).
• Gestating or Lactating women.
• Pleural effusion, pericardial effusion or ascites that need diuretics or draining within 2 weeks prior to first dose.
• The patient is currently using a drug known to be a strong inhibitor or inducer of CYP3A4.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dose escalation; Participants will receive SCR-6920 capsule orally at escalating doses, till the maximum tolerated dose level is reached, and the recommended phase 2 dose(RP2D) will be determined.	Drug: SCR-6920 capsule; SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis; Other Names: PRMT5 inhibitor; Drug: SCR-6920 capsule; SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis; Other Names: PRMT5 inhibitor
Experimental: Dose expansion: non small cell lung cancer(NSCLC); Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose	Drug: SCR-6920 capsule; SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis; Other Names: PRMT5 inhibitor; Drug: SCR-6920 capsule; SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis; Other Names: PRMT5 inhibitor
Experimental: Dose expansion: NHL; Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose on a continuous basis	Drug: SCR-6920 capsule; SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis; Other Names: PRMT5 inhibitor; Drug: SCR-6920 capsule; SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis; Other Names: PRMT5 inhibitor
Experimental: Dose expansion: solid tumors; Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose on a continuous basis	Drug: SCR-6920 capsule; SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis; Other Names: PRMT5 inhibitor; Drug: SCR-6920 capsule; SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis; Other Names: PRMT5 inhibitor

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose limiting toxicity(DLT)	DLT will be evaluated within 28 days since first dose. The number of DLTs will be used to determine the maximum tolerated dose (MTD).	Up to 28 days
Overall Response Rate (ORR)	Participants with solid tumor: ORR based on RECIST1.1 criteria; Participants with NHL: ORR based on Lugano criteria	Up to approximately 1 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with any adverse events (AEs), serious adverse events (SAEs), withdrawal due to AEs, dose interruptions and reductions	All AEs, SAEs and dose modifications will be collected. Adverse events as characterized by type, severity, timing and relationship to study therapy. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)	Up to approximately 1 years
Number of participants with clinically significant changes in laboratory parameters, vital signs, electrocardiogram (ECG), physical examination and organ-specific parameters.	Blood and urine samples will be collected for analysis of lab parameters. Vital signs, electrocardiogram (ECG), physical examinations and organ-specific parameters will be collected at specified time points. Number of participants with clinically significant changes in laboratory parameters, vital signs, electrocardiogram (ECG), physical examination and organ-specific parameters will be reported.	Up to approximately 1 years
Pharmacokinetic Parameters: Area Under the Curve (AUC)	Blood samples will be collected at given time points to determine the AUC (0-t) and AUC (0-inf) of SCR-6920	Up to approximately 1 years
Pharmacokinetic Parameters: Maximum Concentration (Cmax)	Blood samples will be collected at given time points to determine the Cmax of SCR-6920.	Up to approximately 1 years
Pharmacokinetic Parameters: Trough Concentration (Ctrough)	Blood samples will be collected at given time points to determine the Ctrough of SCR-6920.	Up to approximately 1 years
Pharmacokinetic Parameters: Time to Maximum Concentration (Tmax)	Blood samples will be collected at given time points to determine the Tmax of SCR-6920.	Up to approximately 1 years
Pharmacokinetic Parameters: Terminal elimination half life (t1/2)	Blood samples will be collected at given time points to determine the t1/2 of SCR-6920.	Up to approximately 1 years
Change from Baseline in symmetrical arginine dimethylation (SDMA) as a PD measure	Evaluation of change from baseline in SDMA, a PD biomarker of PRMT5 inhibition.	Up to approximately 1 years

Collaborators and Investigators

• Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): May 18, 2022
• Primary Completion (Anticipated): October 1, 2027
• Study Completion (Anticipated): October 1, 2027

Study Registration Dates

• First Submitted: May 10, 2022
• First Submitted That Met QC Criteria: September 2, 2022
• First Posted (Actual): September 6, 2022

Study Record Updates

• Last Update Posted (Actual): September 6, 2022
• Last Update Submitted That Met QC Criteria: September 2, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: SIM1907-04-PRMT5-101

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No